Vitality Biopharma Reports on Initial Cannabinoid Drug Formulation Studies – SYS

LOS ANGELES, CA — (Marketwired) — 10/19/16 — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced results of recent drug formulation studies that documented substantial modifications to

... read more at: